Pharming Group NV (Pharming) is a biopharmaceutical company focused on developing protein replacement therapies and precision medicines for rare diseases and areas of high unmet medical need. Its lead commercial product is Ruconest (conestat alfa), a recombinant human C1 inhibitor (rhC1INH) used to treat acute hereditary angioedema (HAE) attacks by controlling swelling in affected tissues. Ruconest is marketed directly in the US, the UK, and the European Union, and through distribution partners in South Korea, Israel, and selected Central and South American markets. Pharming is also developing a next-generation, low-volume Ruconest formulation designed for intramuscular administration.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Pharming is engaged in research and development initiatives focused on transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is developing a portfolio of innovative medicines, including small molecules and biologics. Key development programs include treatments for Activated Phosphoinositide 3-kinase Delta (PI3Kd) syndrome (APDS), primary immunodeficiencies (PIDs) with immune dysregulation, and common variable immunodeficiency (CVID) with immune dysregulation. Additionally, Pharming is conducting a pivotal clinical study for KL1333, targeting mitochondrial DNA-driven primary mitochondrial disease. The R&D unit is located near Paris, France, and is responsible for managing the company's research and development activities, including the development of innovative medicines and conducting clinical trials. In FY2025, the company spent US$96.6 million on R&D, which, as a percentage of revenue, stood at 25.6% and grew 18.6% YoY. As of December 2025, the company owned 69 granted patents related to Ruconest, of which five are US-issued, and four pending patent applications, of which two are US pending patent applications. It also holds non-US jurisdictions' issued or pending patent applications in the UK, China, Japan, Canada, Israel, Australia, and New Zealand. The company also has an exclusive license from Novartis to 157 granted patents related to leniolisib, of which three are US-issued and eight pending patent applications, including one pending patent application in the US.